PI3K

Phosphoinositide 3-kinase

PI3K

PI3K Isoform Specific Products:

PI3K Isoform Comparison

PI3K Related Products (626)
Antibodies (16)
PI3K Signaling Pathway
PI3K Isoform Comparison

By Effects:	Controls (4) Ligands (2) Inhibitors (520) Agonist (1) Activators (53) Modulators (17) Inducer (1)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-114428

P110δ-IN-1	Inhibitor	98.44%
P110δ-IN-1 is a potent and selective inhibitor of P110δ extracted from patent WO 2014055647 A1, with an IC₅₀ of 8.4 nM.

HY-10220

SF1126
SF1126 is a relevant pan and dual first-in-class PI3K/BRD4 inhibitor, has antitumor and anti-angiogenic activity. SF1126 is an RGDS-conjugated LY294002 proagent, which is designed to exhibit increased solubility and bind to specific integrins within the tumor compartment. SF1126 induces cell apoptosis.

HY-132231

FD223	Inhibitor	98.05%
FD223 is a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor. FD223 displays high potency (IC₅₀=1 nM) and good selectivity over other isoforms (IC₅₀s of 51 nM, 29 nM and 37 nM, respectively for α, β and γ). FD223 exhibits efficient inhibition of the proliferation of acute myeloid leukemia (AML) cell lines by suppressing p-AKT Ser473 thus causing G1 phase arrest during the cell cycle. FD223 has potential for the research of leukemia such as AML.

HY-112608

CHMFL-PI3KD-317	Inhibitor	98.04%
CHMFL-PI3KD-317 is a highly potent, selective and orally active PI3Kδ inhibitor, with an IC₅₀ of 6 nM, and exhibits over 10-1500 fold selectivity over other class I, II and III PIKK family isoforms, such as PI3Kα (IC₅₀, 62.6 nM), PI3Kβ (IC₅₀, 284 nM), PI3Kγ (IC₅₀, 202.7 nM), PIK3C2A (IC₅₀, >10000 nM), PIK3C2B (IC₅₀, 882.3 nM), VPS34 (IC₅₀, 1801.7 nM), PI4KIIIA (IC₅₀, 574.1 nM) and PI4KIIIB (IC₅₀, 300.2 nM). CHMFL-PI3KD-317 inhibits PI3Kδ-mediated Akt T308 phosphorylation in Raji cells, with an EC₅₀ of 4.3 nM. CHMFL-PI3KD-317 has antiproliferative effects on cancer cells.

HY-11080A

PKI-179 hydrochloride	Inhibitor	99.66%
PKI-179 hydrochloride is a potent and orally active dual PI3K/mTOR inhibitor, with IC₅₀s of 8 nM, 24 nM, 74 nM, 77 nM, and 0.42 nM for PI3K-α, PI3K-β, PI3K-γ, PI3K-δ and mTOR, respectively. PKI-179 hydrochloride also exhibits activity over E545K and H1047R, with IC₅₀s of 14 nM and 11 nM, respectively. PKI-179 hydrochloride shows anti-tumor activity in vivo.

HY-N0728S3

α-Linolenic acid-¹³C₁₈	Inhibitor
α-Linolenic acid-¹³C₁₈ is the ¹³C labeled α-Linolenic acid. α-Linolenic acid, isolated from seed oils, is an essential fatty acid that cannot be synthesized by humans. α-Linolenic acid can affect the process of thrombotic through the modulation of PI3K/Akt signaling. α-Linolenic acid possess the anti-arrhythmic properties and is related to cardiovascular disease and cancer[1].

HY-N4042

Hirsutenone	Inhibitor	99.74%
Hirsutenone is an active botanical diarylheptanoid present in Alnus species and exhibits many biological activities, including anti-inflammatory, anti-tumor promoting and anti-atopic dermatitis effects. Hirsutenone attenuates adipogenesis by binding directly to PI3K and ERK1 in a non-ATP competitive manner. Hirsutenone can be used for the study of obesity.

HY-N7635

Oleanolic acid 28-O-β-D-glucopyranoside	Inhibitor	99.42%
Oleanolic acid 28-O-β-D-glucopyranoside (β-D-Glucopyranosyl oleanolate) is an orally active pentacyclic triterpenoid compound. Oleanolic acid 28-O-β-D-glucopyranoside has anti-inflammatory effects. In ulcerative colitis models, Oleanolic acid 28-O-β-D-glucopyranoside can inhibit the inflammatory response, enhance the intestinal epithelial barrier function, and modulate the gut microbiota. Its mechanism of action is related to the PI3K-AKT and MAPK signaling pathways. Oleanolic acid 28-O-β-D-glucopyranoside can be used in the research of diseases such as colitis.

HY-N9942

Physalin A	Inhibitor	99.22%
Physalin A is a biologically active withanolide. Physalin A shows anti-inflammatory, antifibrotic and ameliorative effects on autophagy in models of disc degeneration. Physalin A has antitumor activity and can induce apoptosis, ROS production and G2/M phase cell cycle arrest. Besides. Physalin A can significantly increase the activity of quinone reductase and increase the expression of detoxifying enzymesc.

HY-10812

GNE-490	Inhibitor
GNE-490, a (thienopyrimidin-2-yl)aminopyrimidine, is a potent pan-PI3K inhibitor with IC₅₀s of 3.5 nM, 25 nM, 5.2 nM, 15 nM for PI3Kα, PI3Kβ, PI3Kδ and PI3Kγ, respectively. GNE-490 has >200 fold selectivity for mTOR (IC₅₀=750 nM). GNE-490 shows potent suppression efficacy profile against MCF7.1 breast cancer xenograft model.

HY-11105

Pilaralisib analogue	Inhibitor	99.74%
Pilaralisib analogue (XL147 analogue) is a representative and selective PI3Kα inhibitor extracted from patent WO2012006552A1, Compound 147 in Table 1.

HY-111510

IPI-3063	Inhibitor	99.22%
IPI-3063 is a potent and selective PI3K p110δ inhibitor with an IC₅₀ of 2.5 ± 1.2 nM.

HY-131345A

(S)-PI3Kα-IN-4	Inhibitor	99.77%
(S)-PI3Kα-IN-4 is a potent inhibitor of PI3Kα, with an IC₅₀ of 2.3 nM. (S)-PI3Kα-IN-4 shows 38.3-, 4.25-, and 4.93-fold selectivity for PI3Kα over PI3Kβ, PI3Kδ, and PI3Kγ, respectively. (S)-PI3Kα-IN-4 can be used for the research of cancer.

HY-124036

DS-7423	Inhibitor	99.75%
DS-7423 is a dual PI3K and mTOR inhibitor, with IC₅₀ values of 15.6 nM, 34.9 nM for PI3Kα and mTOR, respectively. DS-7423 possesses anti-tumor activity.

HY-N2590

Lupenone		99.74%
Lupenone is an orally active lupine-type triterpenoid that can be isolated from Musa basjoo. Lupenone Lupenone plays a role through the PI3K/Akt/mTOR and NF-κB signaling pathways. Lupenone has anti-inflammatory, antiviral, antidiabetic and anticancer activities.

HY-N6996R

Methyl Eugenol (Standard)	Inhibitor
Methyl Eugenol (Standard) is the analytical standard of Methyl Eugenol. This product is intended for research and analytical applications. Methyl Eugenol is a bait that has oral activity against oriental fruit fly (Hendel).Methyl Eugenol has anti-cancer and anti-inflammatory activities. Methyl Eugenol can induce Autophagy in cells. Methyl Eugenol can be used in the study of intestinal ischemia/reperfusion injury.

HY-17635S

Leniolisib-d₅	Inhibitor	98.78%
Leniolisib-d5 is a deuterated labeled Leniolisib. Leniolisib (CDZ173) is a potent and selective PI3Kδ inhibitor. Leniolisib has the potential for immunodeficiency disorders treatment.

HY-153120A

PI3K/mTOR Inhibitor-13 sodium	Inhibitor	98.13%
PI3K/mTOR Inhibitor-13 sodium is an orally active dual inhibitor of phosphoinositol 3-kinase (PI3K) and mTOR kinase. PI3K/mTOR Inhibitor-13 sodium has potential applications in sexual diseases, solid tumor and idiopathic pulmonary fibrosis (IPF).

HY-150019

PI3K-IN-36	Inhibitor	98.76%
PI3K-IN-36 (compound A36) is a potent PI3K inhibitor. PI3K-IN-36 can be used in research of follicular lymphoma (FL).

HY-15280

GSK2292767	Inhibitor	98.89%
GSK2292767 is a potent and selective inhibitor of PI3Kδ, with a pIC₅₀ of 10.1. GSK2292767 showing greater than 500-fold selective over the other PI3K isoforms. GSK2292767 can be used for the research of respiratory disease.

Growth factor RTK SHC SOS GRB2 RAS p85 p110α/δ PTEN SHIP1 or
SHIP2 INPP4B p110β p85 RAC1 or CDC Chemokine GPCR p101 p110γ PDK-1 Akt AS160 eNOS p21 RAS-GTP Insulin/GF Insulin/ IGF receptor GRB10 S6K IRS1 PI3K PTEN ZAP70 TCR CD3 RAF MEK ERK MNK eIF4E RSK MYC AMPK BAD FOXOs GSK-3 BCL-X_L BCL-2 BIM p27 FAS ligand Cyclin D BAX TSC2 TSC1 TBC1D7 RHEB Ribosome mLST8 mTOR SIN1 RICTOR TSC2 TSC1 TBC1D7 RAC1 GSK-3β Axin APC Wnt TLR MYD88 RAC1 PI3K INPP4B SHIP1 or
SHIP2 PTEN 4E-BP ULK1 S6K GRB10 mLST8 mTOR RAPTOR mTORC1 p85 p110δ PI3Kδ DAG PKC CARMA1 MALT1 BCL-10 IKKα IKKβ NEMO IκB p50 p65 NF-κB p85α p110δ PI3Kδ CD81 BCAP LYN BLK SYK BLNK BTK PLCγ2 GADs VAV SLP76 ITK PLCγ1 JAK3 ICOS IL-2 IL-2R BCR CD19 mTORC2

Download PI3K Signaling Pathway Map.

Phosphatidylinositol 3 kinases (PI3Ks) are a family of lipid kinases that integrate signals from growth factors, cytokines and other environmental cues, translating them into intracellular signals that regulate multiple signaling pathways. These pathways control many physiological functions and cellular processes, which include cell proliferation, growth, survival, motility and metabolism^[1].

In the absence of activating signals, p85 interacts with p110 and inhibits p110 kinase activity. Following receptor tyrosine kinase (RTK) or G protein-coupled receptor (GPCR) activation, class I PI3Ks are recruited to the plasma membrane, where p85 inhibition of p110 is relieved and p110 phosphorylates PIP2 to generate PIP3. The activated insulin receptor recruits intracellular adaptor protein IRS1. Phosphorylation of IRS proteins on tyrosine residues by the insulin receptor initiates the recruitment and activation of PI3K. PIP3 acts as a second messenger which promotes the phosphorylation of Akt at Thr308 by PDK-1. RTK activation can also trigger Ras-Raf-MEK-ERK pathway. Activated Akt, ERK and RSK phosphorylate TSC2 at multiple sites to inhibit TSC1-TSC2-TBC1D7, which is the TSC complex that acts as a GTPase-activating protein (GAP) for the small GTPase RHEB. During inhibition of the TSC complex, GTP-loaded RHEB binds the mTOR catalytic domain to activate mTORC1. Glycogen synthase kinase 3β (GSK-3β) activates the TSC complex by phosphorylating TSC2 at Ser1379 and Ser1383. Phosphorylation of these two residues requires priming by AMPK-dependent phosphorylation of Ser1387. Wnt signaling inhibits GSK-3β and the TSC complex, and thus activates mTORC1. mTORC2 is activated by Wnt in a manner dependent on the small GTPase RAC1. Akt activation contributes to diverse cellular activities which include cell survival, growth, proliferation, angiogenesis, metabolism, and migration. Important downstream targets of Akt are GSK-3, FOXOs, BAD, AS160, eNOS, and mTOR. mTORC1 negatively regulates autophagy through multiple inputs, including inhibitory phosphorylation of ULK1, and promotes protein synthesis through activation of the translation initiation promoter S6K and through inhibition of the inhibitory mRNA cap binding 4E-BP1^[1][2][3].

PI3Kδ is a heterodimeric enzyme, typically composed of a p85α regulatory subunit and a p110δ catalytic subunit. In T cells, the TCR, the costimulatory receptor ICOS and the IL-2R can activate PI3Kδ. In B cells, PI3Kδ is activated upon crosslinking of the B cell receptor (BCR). The BCR co-opts the co-receptor CD19 or the adaptor B cell associated protein (BCAP), both of which have YXXM motifs to which the p85α SH2 domains can bind. In lumphocytes, BTK and ITK contribute to the activation of PLCγ and promotes the generation of DAG and the influx of Ca²⁺, which in turn activate PKC and the CARMA1-, BCL 10- and MALT1 containing (CBM) complex. The resulting NF-κB inhibitor kinase (IKK) activation leads to the phosphorylation and the degradation of IκB, and to the nuclear accumulation of the p50-p65 NF-κB heterodimer. MyD88 is an adapter protein that mediates signal transduction for most TLRs and leads to activation of PI3K^[4].

Reference:

[1]. Thorpe LM, et al. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting.Nat Rev Cancer. 2015 Jan;15(1):7-24.
[2]. Vanhaesebroeck B, et al. PI3K signalling: the path to discovery and understanding.Nat Rev Mol Cell Biol. 2012 Feb 23;13(3):195-203.
[3]. Fruman DA, et al. The PI3K Pathway in Human Disease.Cell. 2017 Aug 10;170(4):605-635.
[4]. Lucas CL, et al. PI3Kδ and primary immunodeficiencies.Nat Rev Immunol. 2016 Nov;16(11):702-714.

PI3K Isoform Comparison

PI3Kα

PI3Kβ

PI3Kγ

PI3Kδ

PI3KC2α

PI3KC2β

PI3KC2γ

Vps34

PI3K

PI3KC3

p120γ

PI3K Inhibitors, Activators & Modulators

Product Name	PI3Kα	PI3Kβ	PI3Kγ	PI3Kδ	PI3KC2α	PI3KC2β	PI3KC2γ	Vps34	PI3K	PI3KC3	p120γ	Purity

3-Methyladenine

PtdIns3Kγ, IC₅₀: 60 μM (Cell Assay)

Vps34, IC₅₀: 25 μM (Cell Assay)

99.91%

LY294002

p110α, IC₅₀: 0.5 μM

p110β, IC₅₀: 0.97 μM

p110δ, IC₅₀: 0.57 μM

99.95%

Quercetin

PI3Kβ, IC₅₀: 5.4 μM

PI3Kγ, IC₅₀: 3 μM

PI3Kδ, IC₅₀: 2.4 μM

99.80%

740 Y-P

PI3K

99.96%

Alpelisib

p110α, IC₅₀: 5 nM
p110α-H1047R, IC₅₀: 4 nM
p110α-E545K, IC₅₀: 4 nM

p110β, IC₅₀: 1200 nM

p110γ, IC₅₀: 250 nM

p110δ, IC₅₀: 290 nM

99.95%

Wortmannin

PI3K, IC₅₀: 3 nM

99.86%

AZD-7648

PI3Kγ, IC₅₀: 1.37 μM

99.86%

α-Linolenic acid

PI3K

99.92%

Idelalisib

p110α, IC₅₀: 820 nM

p110β, IC₅₀: 565 nM

p110γ, IC₅₀: 89 nM

p110δ, IC₅₀: 2.5 nM

hVps34, IC₅₀: 978 nM

99.78%

Pictilisib

p110α, IC₅₀: 3 nM
p110α-H1047R, IC₅₀: 3 nM
p110α-E545K, IC₅₀: 3 nM

p110β, IC₅₀: 33 nM

p110γ, IC₅₀: 75 nM

p110δ, IC₅₀: 3 nM

99.80%

Inavolisib

PI3Kα, IC₅₀: 0.038 nM

99.96%

Buparlisib

p110α, IC₅₀: 52 nM
p110α-H1047R, IC₅₀: 58 nM
p110α-E545K, IC₅₀: 99 nM

p110β, IC₅₀: 166 nM

p110γ, IC₅₀: 262 nM

p110δ, IC₅₀: 116 nM

Vps34, IC₅₀: 2.4 μM

99.90%

Dactolisib

p110α, IC₅₀: 4 nM
p110α-H1047R, IC₅₀: 4.6 nM
p110α-E545K, IC₅₀: 5.7 nM

p110β, IC₅₀: 75 nM

p110γ, IC₅₀: 5 nM

p110δ, IC₅₀: 7 nM

99.94%

Duvelisib

p110α, IC₅₀: 1602 nM

p110β, IC₅₀: 85 nM

p110γ, IC₅₀: 27.4 nM

p110δ, IC₅₀: 2.5 nM

99.88%

SAR405

Vps34, IC₅₀: 1.2 nM
Vps34, Kd: 1.5 nM

99.74%

Copanlisib

PI3Kα, IC₅₀: 0.5 nM

PI3Kβ, IC₅₀: 3.7 nM

PI3Kγ, IC₅₀: 6.4 nM

PI3Kδ, IC₅₀: 0.7 nM

99.50%

Eganelisib

PI3Kα, IC₅₀: 3.2 μM

PI3Kβ, IC₅₀: 3.5 μM

PI3Kγ, IC₅₀: 16 nM

99.68%

Isorhamnetin

PI3-K

99.94%

Recilisib

PI3K

99.94%

PI-103

p110α, IC₅₀: 8 nM

p110β, IC₅₀: 88 nM

p110γ, IC₅₀: 150 nM

p110δ, IC₅₀: 48 nM

PI3KC2α, IC₅₀: 1 μM

PI3KC2β, IC₅₀: 26 nM

hsVPS34, IC₅₀: 2.3 μM

99.82%

YM-201636

p110α, IC₅₀: 3.3 μM

98.05%

Omipalisib

p110α, Ki: 0.019 nM
p110α-H1047R, Ki: 0.009 nM
p110α-E545K, Ki: 0.008 nM
p110α-E542K, Ki: 0.008 nM

p110β, Ki: 0.13 nM

p110γ, Ki: 0.06 nM

p110δ, Ki: 0.024 nM

99.94%

Copanlisib dihydrochloride

PI3Kα, IC₅₀: 0.5 nM

PI3Kβ, IC₅₀: 3.7 nM

PI3Kγ, IC₅₀: 6.4 nM

PI3Kδ, IC₅₀: 0.7 nM

99.55%

Taselisib

PI3Kα, Ki: 0.29 nM

PI3Kβ, Ki: 9.1 nM

PI3Kγ, Ki: 0.97 nM

PI3Kδ, Ki: 0.12 nM

99.75%

Vps34-IN-1

Vps34, IC₅₀: 25 nM

99.79%

hSMG-1 inhibitor 11j

PI3Kα, IC₅₀: 92 nM

PI3Kγ, IC₅₀: 60 nM

99.82%

Fimepinostat

PI3Kα, IC₅₀: 19 nM

PI3Kβ, IC₅₀: 54 nM

PI3Kγ, IC₅₀: 311 nM

PI3Kδ, IC₅₀: 39 nM

99.95%

PI3K/AKT-IN-1

PI3Kγ, IC₅₀: 6.99 μM

PI3Kδ, IC₅₀: 4.01 μM

99.64%

Gedatolisib

PI3Kα, IC₅₀: 0.4 nM
PI3Kα-H1047R, IC₅₀: 0.6 nM
PI3Kα-E545K, IC₅₀: 0.6 nM

PI3Kβ, IC₅₀: 6 nM

PI3Kγ, IC₅₀: 5.4 nM

PI3Kδ, IC₅₀: 6 nM

99.68%

Autophinib

Vps34, IC₅₀: 19 nM

99.95%

Esculetin

PI3K

99.79%

Quercetin dihydrate

PI3Kβ, IC₅₀: 5.4 μM

PI3Kγ, IC₅₀: 2.4 μM

PI3Kδ, IC₅₀: 3.0 μM

Thymoquinone

PI3K

99.80%

Dihydrocapsaicin

PI3K

99.93%

GSK2636771

PI3Kβ, Ki: 0.89 nM
PI3Kβ, IC₅₀: 5.2 nM

99.59%

PIK-90

p110α, IC₅₀: 11 nM

p110β, IC₅₀: 350 nM

p110γ, IC₅₀: 18 nM

p110δ, IC₅₀: 58 nM

PI3KC2α, IC₅₀: 47 nM

PI3KC2β, IC₅₀: 64 nM

hsVPS34, IC₅₀: 830 nM

99.70%

Paxalisib

PI3Kα, Ki: 2 nM

PI3Kβ, Ki: 46 nM

PI3Kγ, Ki: 10 nM

PI3Kδ, Ki: 3 nM

99.63%

Umbralisib

PI3Kα, Kd: >10000 nM

PI3Kβ, Kd: >10000 nM

PI3Kγ, Kd: 1400 nM

PI3Kδ, EC₅₀: 22.2 nM
PI3Kδ, Kd: 6.2 nM

98.94%

ZSTK474

PI3Kα, IC₅₀: 16 nM

PI3Kβ, IC₅₀: 44 nM

PI3Kγ, IC₅₀: 49 nM

PI3Kδ, IC₅₀: 4.6 nM

99.71%

PF-04691502

PI3Kα, Ki: 1.8 nM

PI3Kβ, Ki: 2.1 nM

PI3Kγ, Ki: 1.9 nM

PI3Kδ, Ki: 1.6 nM

99.91%

hSMG-1 inhibitor 11e

PI3Kα, IC₅₀: 61 nM

PI3Kγ, IC₅₀: 92 nM

99.81%

AZD 6482

PI3Kα, IC₅₀: 136 nM

PI3Kβ, IC₅₀: 0.69 nM

PI3Kγ, IC₅₀: 47.8 nM

PI3Kδ, IC₅₀: 13.6 nM

PI3K-C2β, IC₅₀: 54.1 nM

hVps34, IC₅₀: 3390 nM

99.93%

GO-203 TFA

PI3K

99.28%

Samotolisib

PI3Kα, IC₅₀: 6.07 nM

PI3Kβ, IC₅₀: 77.6 nM

PI3Kγ, IC₅₀: 23.8 nM

PI3Kδ, IC₅₀: 38 nM

99.27%

AS-252424

PI3Kα, IC₅₀: 935 nM

PI3Kβ, IC₅₀: 20 μM

PI3Kγ, IC₅₀: 30 nM

PI3Kδ, IC₅₀: 20 μM

99.71%

PIK-93

p110α, IC₅₀: 39 nM

p110β, IC₅₀: 590 nM

p110γ, IC₅₀: 16 nM

p110δ, IC₅₀: 120 nM

PI3KC2α, IC₅₀: 16 μM

PI3KC2β, IC₅₀: 140 nM

hsVPS34, IC₅₀: 320 nM

99.81%

Linperlisib

PI3Kδ, IC₅₀: 6.4 nM

99.51%

TGX-221

p110β, IC₅₀: 8.5 nM

p110δ, IC₅₀: 211 nM

99.74%

Vps34-PIK-III

PI(3)Kα, IC₅₀: 3.96 μM

PI(3)Kγ, IC₅₀: 3.04 μM

PI(3)Kδ, IC₅₀: 1.2 μM

Vps34, IC₅₀: 18 nM

99.63%

Apitolisib

PI3Kα, IC₅₀: 5 nM

PI3Kβ, IC₅₀: 27 nM

PI3Kγ, IC₅₀: 14 nM

PI3Kδ, IC₅₀: 7 nM

99.29%

Bimiralisib

PI3Kα, IC₅₀: 33 nM
PI3Kα-H1047R, IC₅₀: 36 nM
PI3Kα-E545K, IC₅₀: 136 nM
PI3Kα-E542K, IC₅₀: 63 nM

PI3Kβ, IC₅₀: 661 nM

PI3Kγ, IC₅₀: 708 nM

PI3Kδ, IC₅₀: 451 nM

Vps34, IC₅₀: 6486 nM

99.80%

AZD8186

PI3Kα, IC₅₀: 35 nM

PI3Kβ, IC₅₀: 4 nM

PI3Kγ, IC₅₀: 675 nM

PI3Kδ, IC₅₀: 12 nM

99.95%

TG100-115

PI3Kγ, IC₅₀: 83 nM

PI3Kδ, IC₅₀: 235 nM

99.41%

Sophocarpine

PI3K

98.63%

Leniolisib

PI3Kα, IC₅₀: 280 nM

PI3Kβ, IC₅₀: 480 nM

PI3Kγ, IC₅₀: 2.57 μM

PI3Kδ, IC₅₀: 11 nM

99.28%

Parsaclisib

PI3Kδ, IC₅₀: 1 nM

99.31%

Dactolisib Tosylate

p110α, IC₅₀: 4 nM
p110α-H1047R, IC₅₀: 4.6 nM
p110α-E545K, IC₅₀: 5.7 nM

p110β, IC₅₀: 75 nM

p110γ, IC₅₀: 5 nM

p110δ, IC₅₀: 7 nM

99.87%

Voxtalisib

p110α, IC₅₀: 39 nM

p110β, IC₅₀: 113 nM

p110γ, IC₅₀: 9 nM

p110δ, IC₅₀: 43 nM

99.02%

PI3K-IN-1

PI3K

99.93%

PI3K-IN-30

PI3Kα, IC₅₀: 5.1 nM

PI3Kβ, IC₅₀: 136 nM

PI3Kγ, IC₅₀: 30.7 nM

PI3Kδ, IC₅₀: 8.9 nM

98.21%

CNX-1351

PI3Kα, IC₅₀: 6.8 nM

PI3Kβ, IC₅₀: 166 nM

PI3Kγ, IC₅₀: 3020 nM

PI3Kδ, IC₅₀: 240.3 nM

99.88%

BGT226

PI3Kα, IC₅₀: 4 nM

PI3Kβ, IC₅₀: 63 nM

PI3Kγ, IC₅₀: 38 nM

99.51%

IC-87114

PI3Kβ, IC₅₀: 75 μM

PI3Kγ, IC₅₀: 29 μM

PI3Kδ, IC₅₀: 0.5 μM

99.83%

Deoxyshikonin

PI3K

99.96%

PIK-75 hydrochloride

p110α, IC₅₀: 5.8 nM

p110β, IC₅₀: 1.3 μM

p110γ, IC₅₀: 76 nM

p110δ, IC₅₀: 510 nM

PI3KC2α, IC₅₀: 10 μM

PI3KC2β, IC₅₀: 1 μM

hsVPS34, IC₅₀: 2.6 μM

99.72%

Pilaralisib

PI3Kα, IC₅₀: 39 nM

PI3Kβ, IC₅₀: 383 nM

PI3Kγ, IC₅₀: 23 nM

PI3Kδ, IC₅₀: 36 nM

Vps34, IC₅₀: 6974 nM

99.14%

KU-0060648

PI3Kα, IC₅₀: 4 nM

PI3Kβ, IC₅₀: 0.5 nM

PI3Kγ, IC₅₀: 0.594 μM

PI3Kδ, IC₅₀: 0.1 nM

99.62%

Flupentixol dihydrochloride

PI3Kα, IC₅₀: 127 nM

99.73%

1,3-Dicaffeoylquinic acid

PI3K

99.09%

Serabelisib

p110α, IC₅₀: 15 nM

p110β, IC₅₀: 4500 nM

p110γ, IC₅₀: 1900 nM

p110δ, IC₅₀: 13900 nM

99.44%

GSK1059615

PI3Kα, IC₅₀: 0.4 nM

PI3Kβ, IC₅₀: 0.6 nM

PI3Kγ, IC₅₀: 2 nM

PI3Kδ, IC₅₀: 5 nM

≥99.0%

PKI-402

PI3Kα, IC₅₀: 2 nM
PI3Kα-H1047R, IC₅₀: 3 nM
PI3Kα-E545K, IC₅₀: 3 nM

PI3Kβ, IC₅₀: 7 nM

PI3Kγ, IC₅₀: 16 nM

PI3Kδ, IC₅₀: 14 nM

98.43%

VS-5584

PI3Kα, IC₅₀: 16 nM

PI3Kβ, IC₅₀: 68 nM

PI3Kγ, IC₅₀: 25 nM

PI3Kδ, IC₅₀: 42 nM

Vps34, IC₅₀: 7470 nM

99.14%

AS-605240

PI3Kα, IC₅₀: 60 nM

PI3Kβ, IC₅₀: 270 nM

PI3Kγ, IC₅₀: 8 nM
PI3Kγ, Ki: 7.8 nM

PI3Kδ, IC₅₀: 300 nM

98.51%

GNE-317

PI3K

99.14%

SAR-260301

PI3Kα, IC₅₀: 1539 nM

PI3Kβ, IC₅₀: 23 nM

PI3Kγ, IC₅₀: 10000 nM

PI3Kδ, IC₅₀: 468 nM

PI3KC2γ, IC₅₀: 3812 nM

Vps34, IC₅₀: 183 nM

99.95%

CGS 15943

p110γ, IC₅₀: 1.1 μM

p110δ, IC₅₀: 8.47 μM

99.96%

Buparlisib Hydrochloride

p110α, IC₅₀: 52 nM
p110α-H1047R, IC₅₀: 58 nM
p110α-E545K, IC₅₀: 99 nM

p110β, IC₅₀: 166 nM

p110γ, IC₅₀: 262 nM

p110δ, IC₅₀: 116 nM

Vps34, IC₅₀: 2.4 μM

99.88%

PI-103 Hydrochloride

p110α, IC₅₀: 2 nM

p110β, IC₅₀: 3 nM

p110γ, IC₅₀: 15 nM

p110δ, IC₅₀: 3 nM

98.55%

A66

p110α, IC₅₀: 32 nM
p110α E545K, IC₅₀: 30 nM
p110α H1047R, IC₅₀: 43 nM

p110γ, IC₅₀: 3480 nM

PI3K-C2β, IC₅₀: 462 nM

99.73%

PI3Kγ inhibitor AZ2

PI3Kα, pIC₅₀: 5.1

PI3Kβ, pIC₅₀: 4.5

PI3Kγ, pIC₅₀: 9.3

PI3Kδ, pIC₅₀: 6.6

99.25%

AMG319

PI3Kα, IC₅₀: 33 μM

PI3Kβ, IC₅₀: 2.7 μM

PI3Kγ, IC₅₀: 850 nM

PI3Kδ, IC₅₀: 18 nM

99.08%

Tenalisib

PI3Kγ, IC₅₀: 33 nM

PI3Kδ, IC₅₀: 25 nM

98.83%

PQR530

PI3Kα, Kd: 0.84 nM

PI3Kβ, Kd: 6.1 nM

PI3Kγ, Kd: 10 nM

PI3Kδ, Kd: 11 nM

PI3KC2β, Kd: 100 nM

99.98%

Roginolisib

PI3Kα, IC₅₀: 18500 nM

PI3Kβ, IC₅₀: 2850 nM

PI3Kδ, IC₅₀: 145 nM

99.89%

MTX-531

PI3Kα, IC₅₀: 6.4 nM

PI3Kβ, IC₅₀: 233 nM

PI3Kγ, IC₅₀: 8.3 nM

PI3Kδ, IC₅₀: 1.1 nM

99.87%

SF2523

PI3Kα, IC₅₀: 34 nM

PI3Kγ, IC₅₀: 158 nM

98.25%

Ginkgolic Acid (C13:0)

PI3Kδ, IC₅₀: 2.49 μM

99.92%

Nemiralisib

PI3Kα, pIC₅₀: 5.3

PI3Kβ, pIC₅₀: 5.8

PI3Kγ, pIC₅₀: 5.2

PI3Kδ, pKi: 9.9

99.80%

Zandelisib

PI3Kδ, IC₅₀: 3.5 nM

99.90%

AZD3458

PI3Kα, pIC₅₀: 5.1

PI3Kβ, pIC₅₀: 4.5

PI3Kγ, pIC₅₀: 9.1

PI3Kδ, pIC₅₀: 6.5

PI3KC2α, pIC₅₀: 5

PI3KC2β, pIC₅₀: 7.5

PI3KC2γ, pIC₅₀: 5.5

PI3KC3, pIC₅₀: 5.1

99.71%

BAY1082439

PI3Kα

PI3Kβ

PI3Kδ

98.02%

BGT226 maleate

PI3Kα, IC₅₀: 4 nM

PI3Kβ, IC₅₀: 63 nM

PI3Kγ, IC₅₀: 38 nM

99.92%

Duvelisib (R enantiomer)

PI3K

99.00%

Pictilisib dimethanesulfonate

p110α, IC₅₀: 3 nM
p110α-H1047R, IC₅₀: 3 nM
p110α-E545K, IC₅₀: 3 nM

p110β, IC₅₀: 33 nM

p110γ, IC₅₀: 75 nM

p110δ, IC₅₀: 3 nM

99.72%

Sonolisib

p110α, IC₅₀: 0.1 nM

p110δ, IC₅₀: 2.9 nM

p120γ, IC₅₀: 1 nM

99.00%

Brevianamide F

PI3Kα, IC₅₀: 4.8 μM

99.03%

GNE-493

PI3Kα, IC₅₀: 3.4 nM

PI3Kβ, IC₅₀: 12 nM

PI3Kγ, IC₅₀: 16 nM

PI3Kδ, IC₅₀: 16 nM

99.81%

GDC-0326

PI3Kα, Ki: 0.2 nM

PI3Kβ, Ki: 26.6 nM

PI3Kγ, Ki: 10.2 nM

PI3Kδ, Ki: 4 nM

99.92%

PF-06843195

PI3Kα, IC₅₀: 18 nM (in Rat1 fibroblasts)
PI3Kα, Ki: 0.018 nM

PI3Kβ, IC₅₀: 360 nM (in Rat1 fibroblasts)

PI3Kδ, IC₅₀: 160 nM (in Rat1 fibroblasts)
PI3Kδ, Ki: 0.28 nM

98.01%

PF-04979064

PI3Kα, Ki: 0.13 nM

PI3Kγ, Ki: 0.111 nM

PI3Kδ, Ki: 0.122 nM

99.54%

Sophocarpine monohydrate

PI3K

99.91%

alpha-Bisabolol

PI3K

Glaucocalyxin A

PI3K

99.39%

4-Methylbenzylidene camphor

PI3K

99.87%

PI4KIIIbeta-IN-9

PI3Kα, IC₅₀: 2 μM

PI3Kγ, IC₅₀: 1046 nM

PI3Kδ, IC₅₀: 152 nM

PI3KC2γ, IC₅₀: 1 μM

99.18%

Vps34-IN-2

Vps34, IC₅₀: 2 nM

99.81%

AS-604850

PI3Kα, IC₅₀: 4.5 μM

PI3Kγ, IC₅₀: 0.25 μM
PI3Kγ, Ki: 0.18 μM

99.95%

PI3Kα-IN-9

PI3Kα, IC₅₀: 4.4 nM

PI3Kβ, IC₅₀: 153 nM

PI3Kγ, IC₅₀: 128 nM

PI3Kδ, IC₅₀: 146 nM

99.17%

YH-306

PI3K

98.34%

Izorlisib

PI3Kα, IC₅₀: 14 nM
PI3Kα-H1047R, IC₅₀: 5.6 nM
PI3Kα-E545K, IC₅₀: 6.7 nM
PI3Kα-E542K, IC₅₀: 6.7 nM

PI3Kβ, IC₅₀: 120 nM

PI3Kγ, IC₅₀: 36 nM

PI3Kδ, IC₅₀: 500 nM

PI3KC2β, IC₅₀: 5.3 μM

99.01%

PI-3065

p110α, IC₅₀: 910 nM

p110β, IC₅₀: 600 nM

p110δ, IC₅₀: 5 nM

98.97%

AZD8154

PI3Kγ

99.88%

PI3K/mTOR Inhibitor-2

PI3Kα, IC₅₀: 3.4 nM

PI3Kβ, IC₅₀: 34 nM

PI3Kγ, IC₅₀: 1 nM

PI3Kδ, IC₅₀: 16 nM

99.10%

Hederacolchiside A1

PI3K

≥99.0%

PI3K-IN-31

PI3Kα, IC₅₀: 3.7 nM

PI3Kβ, IC₅₀: 74 nM

PI3Kγ, IC₅₀: 14.6 nM

PI3Kδ, IC₅₀: 9.9 nM

99.55%

AMG 511

PI3Kα, Ki: 4 nM

PI3Kβ, Ki: 6 nM

PI3Kγ, Ki: 1 nM

PI3Kδ, Ki: 2 nM

99.38%

PIK-75

p110α, IC₅₀: 5.8 nM

p110β, IC₅₀: 1.3 μM

p110γ, IC₅₀: 76 nM

p110δ, IC₅₀: 510 nM

PI3KC2α, IC₅₀: 10 μM

PI3KC2β, IC₅₀: 1 μM

hsVPS34, IC₅₀: 2.6 μM

99.94%

PI4K-IN-1

PI3Kα, pIC₅₀: 4.0

PI3Kβ, pIC₅₀: <3.7

PI3Kγ, pIC₅₀: 5.0

PI3Kδ, pIC₅₀: <4.1

98.61%

GSK-F1

PI3KA, pIC₅₀: 5.8
PI3KB, pIC₅₀: 5.9
PI3KG, pIC₅₀: 5.9
PI3KD, pIC₅₀: 6.4

NSC781406

PI3Kα, IC₅₀: 2 nM

PI3Kβ, IC₅₀: 9.4 nM

PI3Kγ, IC₅₀: 2.7 nM

PI3Kδ, IC₅₀: 14 nM

99.97%

Leniolisib phosphate

PI3Kα, IC₅₀: 280 nM

PI3Kβ, IC₅₀: 480 nM

PI3Kγ, IC₅₀: 2.57 nM

PI3Kδ, IC₅₀: 11 nM

99.10%

HS-173

PI3Kα, IC₅₀: 0.8 nM

99.04%

MTX-211

PI3K

99.81%

IITZ-01

PI3Kγ, IC₅₀: 2.62 μM

98.18%

Acalisib

p110α, IC₅₀: 5441 nM

p110β, IC₅₀: 3377 nM

p110γ, IC₅₀: 1389 nM

p110δ, IC₅₀: 12.7 nM

hVps34, IC₅₀: 12682 nM

99.98%

AQX-016A

PI3K

98.00%

Polygalasaponin F

PI3K

99.85%

PI3K/mTOR Inhibitor-4

PI3Kα, IC₅₀: 0.63 nM

PI3Kβ, IC₅₀: 94.54 nM

PI3Kγ, IC₅₀: 22 nM

PI3Kδ, IC₅₀: 9.2 nM

GNE-477

PI3Kα, IC₅₀: 4 nM

98.75%

AZD-8835

PI3Kα, IC₅₀: 6.2 nM
PI3Kα-E545K, IC₅₀: 6 nM
PI3Kα-H1047R, IC₅₀: 5.8 nM

PI3Kβ, IC₅₀: 431 nM

PI3Kγ, IC₅₀: 90 nM

PI3Kδ, IC₅₀: 5.7 nM

98.62%

Seletalisib

PI3Kδ, IC₅₀: 12 nM

99.79%

ETP-45658

PI3Kα, IC₅₀: 22.0 nM

PI3Kβ, IC₅₀: 129.0 nM

PI3Kγ, IC₅₀: 717.3 nM

PI3Kδ, IC₅₀: 39.8 nM

98.97%

CZC24832

PI3Kβ, IC₅₀: 1.1 μM

PI3Kγ, IC₅₀: 27 nM

PI3Kδ, IC₅₀: 8.194 μM

99.07%

PKI-179

PI3Kα, IC₅₀: 8 nM

PI3Kβ, IC₅₀: 24 nM

PI3Kγ, IC₅₀: 74 nM

PI3Kδ, IC₅₀: 77 nM

≥98.0%

PI-828

p110α, IC₅₀: 173 nM

99.62%

PIK-294

p110α, IC₅₀: 10 μM

p110β, IC₅₀: 490 nM

p110γ, IC₅₀: 160 nM

p110δ, IC₅₀: 10 nM

99.90%

PI3K/mTOR Inhibitor-11

PI3Kα, IC₅₀: 3.5 nM

PI3Kδ, IC₅₀: 4.6 nM

98.74%

SRX3207

PI3Kα, IC₅₀: 861 nM

PI3Kγ, IC₅₀: 11100 nM

PI3Kδ, IC₅₀: 1280 nM

98.50%

CAY10505

PI3Kγ, IC₅₀: 30 nM (Neurons)

99.75%

NVP-BAG956

PI3Kα, IC₅₀: 56 nM

PI3Kβ, IC₅₀: 446 nM

PI3Kγ, IC₅₀: 117 nM

PI3Kδ, IC₅₀: 35 nM

99.21%

Umbralisib hydrochloride

PI3Kα, Kd: >10000 nM

PI3Kβ, Kd: >10000 nM

PI3Kγ, Kd: 1400 nM

PI3Kδ, EC₅₀: 22.2 nM
PI3Kδ, Kd: 6.2 nM

99.04%

TG 100713

PI3Kα, IC₅₀: 165 nM

PI3Kβ, IC₅₀: 215 nM

PI3Kγ, IC₅₀: 50 nM

PI3Kδ, IC₅₀: 24 nM

99.49%

Ifupinostat

PI3Kα, IC₅₀: 0.1 μM

99.60%

KTC1101

PI3Kα, IC₅₀: 3.72 nM

PI3Kβ, IC₅₀: 36.29 nM

PI3Kγ, IC₅₀: 17.09 nM

PI3Kδ, IC₅₀: 1.22 nM

98.09%

WYE-687

PI3K alpha, IC₅₀: 81 nM

PI3K gamma, IC₅₀: 3.11 μM

98.05%

SB02024

Vps34

99.70%

FD223

PI3Kα, IC₅₀: 51 nM

PI3Kβ, IC₅₀: 29 nM

PI3Kγ, IC₅₀: 37 nM

PI3Kδ, IC₅₀: 1 nM

98.05%

CHMFL-PI3KD-317

PI3Kα, IC₅₀: 62.6 nM

PI3Kβ, IC₅₀: 284 nM

PI3Kγ, IC₅₀: 202.7 nM

PI3Kδ, IC₅₀: 6 nM

PIK3C2B, IC₅₀: 882.3 nM

Vps34, IC₅₀: 1801.7 nM

98.04%

PKI-179 hydrochloride

PI3Kα, IC₅₀: 8 nM

PI3Kβ, IC₅₀: 24 nM

PI3Kγ, IC₅₀: 74 nM

PI3Kδ, IC₅₀: 77 nM

99.66%

GNE-490

PI3Kα, IC₅₀: 3.5 nM

PI3Kβ, IC₅₀: 25 nM

PI3Kγ, IC₅₀: 15 nM

PI3Kδ, IC₅₀: 5.2 nM

Pilaralisib analogue

PI3K-alpha

99.74%

IPI-3063

p110α, IC₅₀: 1170 nM

p110β, IC₅₀: 1508 nM

p110γ, IC₅₀: 2187 nM

p110δ, IC₅₀: 2.5 nM

99.22%

(S)-PI3Kα-IN-4

PI3Kα, IC₅₀: 2.3 nM

99.77%

GSK2292767

PI3Kδ, pIC₅₀: 10.1

98.89%

AS-041164

PI3Kα, IC₅₀: 240 nM

PI3Kβ, IC₅₀: 1.4 μM

PI3Kγ, IC₅₀: 70 nM

PI3Kδ, IC₅₀: 1.7 μM

99.02%

ETP-46321

p110α, Ki: 2.3 nM
PI3Kα-H1047R, Ki: 2.33 nM
PI3Kα-E545K, Ki: 1.77 nM
PI3Kα-E542K, Ki: 1.89 nM

p110β, Ki: 170 nM

p110γ, Ki: 179 nM

p110δ, Ki: 14.2 nM

99.34%

ON 146040

PI3Kα, IC₅₀: 14 nM

PI3Kβ, IC₅₀: 3 μM

PI3Kγ, IC₅₀: 1 μM

PI3Kδ, IC₅₀: 20 nM

Parsaclisib hydrochloride

PI3Kδ, IC₅₀: 1 nM

98.74%

LX2343

PI3K, IC₅₀: 15.99 μM

99.80%

Roginolisib hemifumarate

PI3Kδ, IC₅₀: 145 nM

99.80%

PI3K-IN-2

PI3Kα, IC₅₀: 13 nM

PI3Kβ, IC₅₀: 7.1 nM

PI3Kγ, IC₅₀: 8.6 nM

PI3Kδ, IC₅₀: 190 nM

99.62%

PI3Kα-IN-4

PI3Kα, IC₅₀: 1.8 nM

99.76%

Vulolisib

PI3Kα, IC₅₀: 0.2 nM

PI3Kβ, IC₅₀: 168 nM

PI3Kγ, IC₅₀: 90 nM

PI3Kδ, IC₅₀: 49 nM

99.60%

PARP/PI3K-IN-1

PI3Kα, pIC₅₀: 8.25

PI3Kβ, pIC₅₀: 6.54

PI3Kγ, pIC₅₀: 6.08

PI3Kδ, pIC₅₀: 8.13

99.43%

PI3K-IN-37

PI3Kα, IC₅₀: 6 nM

PI3Kβ, IC₅₀: 8 nM

PI3Kδ, IC₅₀: 4 nM

≥99.0%

PI3K-IN-22

PI3Kα, IC₅₀: 0.9 nM

99.50%

OMS14

PI3Kγ

99.09%

WYE-687 dihydrochloride

PI3K alpha, IC₅₀: 81 nM

PI3K gamma, IC₅₀: 3.11 μM

≥98.0%

NVS-PI3-4

PI3Kγ

99.40%

MJ04

PI3Kγ, IC₅₀: 3667 nM

98.08%

TASP0415914

PI3Kγ, IC₅₀: 29 nM

99.02%

PI3K-IN-18

PI3Kα, IC₅₀: 41 nM

≥99.0%

GS-9901

PI3Kδ, IC₅₀: 1 nM

99.97%

CHMFL-PI4K-127

PI3Kα, IC₅₀: 191 ± 36 nM

PI3Kβ, IC₅₀: 392 ± 27 nM

PI3Kγ, IC₅₀: 324 ± 19 nM

PI3Kδ, IC₅₀: 104 ± 3 nM

Vps34, IC₅₀: 681 ± 25 nM

99.94%

PF-4989216

PI3Kα, Ki: 0.6 nM

99.38%

FD274

PI3Kα, IC₅₀: 0.65 nM

PI3Kβ, IC₅₀: 1.57 nM

PI3Kγ, IC₅₀: 0.42 nM

PI3Kδ, IC₅₀: 0.65 nM

99.45%

α-Linolenic acid (Standard)

PI3K

PIK-293

PI3Kα, IC₅₀: 100 μM

PI3Kβ, IC₅₀: 10 μM

PI3Kγ, IC₅₀: 25 μM

PI3Kδ, IC₅₀: 0.24 μM

99.41%

CAL-130 Hydrochloride

p110α, IC₅₀: 115 nM

p110β, IC₅₀: 56 nM

p110γ, IC₅₀: 6.1 nM

p110δ, IC₅₀: 1.3 nM

98.74%

NVP-QAV-572

PI3K, IC₅₀: 10 nM

98.05%

PI3Kδ-IN-15

p110α, IC₅₀: 152 nM

p110β, IC₅₀: 145 nM

p110γ, IC₅₀: 15.3 nM

p110δ, IC₅₀: 0.5 nM

99.52%

PI3Kα/mTOR-IN-1

PI3Kα, Ki: 12.5 nM
PI3Kα, IC₅₀: 7 nM (Cell Assay)

99.30%

Umbralisib tosylate

PI3Kα, Kd: >10000 nM

PI3Kβ, Kd: >10000 nM

PI3Kγ, Kd: 1400 nM

PI3Kδ, Kd: 6.2 nM

Nemiralisib hydrochloride

PI3Kα, pIC₅₀: 5.3

PI3Kβ, pIC₅₀: 5.8

PI3Kγ, pIC₅₀: 5.2

PI3Kδ, pKi: 9.9

Umbralisib sulfate

PI3Kα, Kd: >10000

PI3Kβ, Kd: >10000

PI3Kγ, Kd: 1400

PI3Kδ, Kd: 6.2

PI3Kδ-IN-8

PI3Kα, IC₅₀: 377.2 nM

PI3Kβ, IC₅₀: 241.6 nM

PI3Kγ, IC₅₀: 17.9 nM

PI3Kδ, IC₅₀: 3.3 nM

LAS191954

PI3Kδ, IC₅₀: 2.6 nM

PI3K/HDAC-IN-1

PI3Kα, IC₅₀: 42 nM

PI3Kβ, IC₅₀: 101 nM

PI3Kγ, IC₅₀: 67 nM

PI3Kδ, IC₅₀: 8.1 nM

PI3K/mTOR Inhibitor-1

PI3Kα, IC₅₀: 20 nM

PI3Kβ, IC₅₀: 376 nM

PI3Kγ, IC₅₀: 204 nM

PI3Kδ, IC₅₀: 46 nM

CHF-6523

PI3Kδ

IHMT-PI3Kδ-372

PI3Kδ, IC₅₀: 14 nM

PI3K-IN-6

PI3Kα, IC₅₀: 850 nM

PI3Kβ, IC₅₀: 7.8 nM

PI3Kδ, IC₅₀: 5.3 nM

PI3Kγ inhibitor 2

PI3Kγ, Ki: 4 nM

PI3Kdelta inhibitor 1

PI3Kδ, IC₅₀: 1.3 nM

PI3K-IN-9

PI3Kδ

PI3Kγ inhibitor 4

PI3Kα, IC₅₀: 300 nM

PI3Kγ, IC₅₀: 40 nM

PI3Kα-IN-6

PI3Kα

PI3K/mTOR Inhibitor-9

PI3Kα, IC₅₀: 6.6 μM

PI3Kβ, IC₅₀: >10 μM

PI3Kγ, IC₅₀: 6.6 μM

PI3Kδ, IC₅₀: 0.8 μM

PI3K-IN-33

PI3Kα, IC₅₀: 11.73 μM

PI3Kβ, IC₅₀: 6.09 μM

PI3Kδ, IC₅₀: 11.18 μM

PI3Kδ-IN-10

PI3Kδ, IC₅₀: 2 nM

PI3Kα-IN-25

PI3Kα

TRPM7-IN-1

PI3K

D-106669

PI3Kα, IC₅₀: 0.129 μM

SN32976

PI3Kα, IC₅₀: 15.1 nM

PI3Kβ, IC₅₀: 461 nM

PI3Kγ, IC₅₀: 110 nM

PI3Kδ, IC₅₀: 134 nM

99.49%

PI3Kα-IN-19

p110α

ATM Inhibitor-3

PI3K

PI3Kδ-IN-11

PI3Kδ, IC₅₀: 27.5 nM

PI3K-IN-38

p110α, IC₅₀: 0.541 μM

PI3Kδ/BET-IN-1

PI3Kδ, IC₅₀: 112 nM

NVP-CLR457

PI3Kα, IC₅₀: 12 ± 1.5 nM

PI3Kβ, IC₅₀: 8.3 ± 1.0 nM

PI3Kγ, IC₅₀: 230 ± 31 nM

PI3Kδ, IC₅₀: 8.3 ± 2.0 nM

TGX-155

PI3Kβ

PI3K-IN-34

PI3Kα, IC₅₀: 8.43 μM

PI3Kβ, IC₅₀: 15.84 μM

PI3Kδ, IC₅₀: 30.62 μM

ATM Inhibitor-4

PI3K

PD-1/PD-L1-IN-54

PI3K

PI3K/HDAC-IN-2

PI3Kα, IC₅₀: 226 nM

PI3Kβ, IC₅₀: 279 nM

PI3Kγ, IC₅₀: 467 nM

PI3Kδ, IC₅₀: 29 nM

PI3K/mTOR Inhibitor-3

PI3K

PI3Kα-IN-5

PI3Kα, IC₅₀: 0.7 nM

SU-11752

p110γ, IC₅₀: 1.1 μM

PP30

p110γ, IC₅₀: 0.68 μM

p110δ, IC₅₀: 0.99 μM

(R)-IHMT-PI3Kδ-372

PI3Kδ, IC₅₀: 19 nM

99.75%

IHMT-PI3K-315

PI3Kγ, IC₅₀: 4.0 nM

PI3Kδ, IC₅₀: 9.1 nM

PI3Kδ-IN-22

PI3Kα, pKi: 7.3

PI3Kβ, pKi: 7.7

PI3Kγ, pKi: 6.5

PI3Kδ, pKi: 9.3

PI3Kα-IN-13

PI3Kα

(Rac)-AZD8186

PI3Kα, IC₅₀: 35 nM

PI3Kβ, IC₅₀: 4 nM

PI3Kγ, IC₅₀: 675

PI3Kδ, IC₅₀: 12

PI3K/mTOR Inhibitor-12

PI3Kα, IC₅₀: 0.06 nM

Umbralisib R-enantiomer

PI3Kδ

99.52%

PI3Kγ ligand 1

PI3Kγ

COX-2/PI3K-IN-2

PI3K, IC₅₀: 2.78 nM

MEK/PI3K-IN-2

PI3Kα, IC₅₀: 107 ± 21 nM

PI3Kβ, IC₅₀: 3880 ± 725 nM

PI3Kγ, IC₅₀: 2567 ± 364 nM

PI3Kδ, IC₅₀: 137 ± 7 nM

ATR-IN-15

PI3K, IC₅₀: 5131 nM

PH14

PI3Kα, IC₅₀: 20.3 nM

99.29%

PI3Kδ/γ-IN-3

PI3Kγ, IC₅₀: 16 nM

PI3Kδ, IC₅₀: 1 nM

PP487

p110α, IC₅₀: 0.046 μM

p110β, IC₅₀: 0.24 μM

p110γ, IC₅₀: 0.1 μM

p110δ, IC₅₀: 0.027 μM

PI3Kδ-IN-20

PI3Kδ, IC₅₀: 6.4 nM

PI3Kα-IN-7

PI3Kα

PI3Kβ

PI3K-IN-35

PI3Kα, IC₅₀: 13.98 μM

PI3Kβ, IC₅₀: 7.22 μM

PI3Kδ, IC₅₀: 10.94 μM

PI3Kα-IN-11

PI3Kα

PI3Kγ inhibitor 7

PI3Kα, IC₅₀: 4768 nM

PI3Kβ, IC₅₀: 878.1 nM

PI3Kγ, IC₅₀: 3.42 nM

PI3Kδ, IC₅₀: 355.2 nM

17β-Hydroxywortmannin

PI3K, IC₅₀: 0.5 nM

MEK/PI3K-IN-1

PI3Kα, IC₅₀: 130 ± 13 nM

PI3Kβ, IC₅₀: 1537 ± 188 nM

PI3Kγ, IC₅₀: 2745 ± 485 nM

PI3Kδ, IC₅₀: 236 ± 29 nM

PI3K/mTOR Inhibitor-8

PI3Kα, IC₅₀: 0.46 nM

XJTU-L453

PI3Kα

Flupentixol

PI3Kα, IC₅₀: 127 nM

IHMT-PI3K-455

PI3Kα, IC₅₀: 6.717 μM

PI3Kβ, IC₅₀: 42.04 nM

PI3Kγ, IC₅₀: 7.1 nM

PI3Kδ, IC₅₀: 0.57 nM

Isorhamnetin (Standard)

PI3-K

PI3Kδ-IN-12

PI3Kα, pKi: 6.7

PI3Kβ, pKi: 6.4

PI3Kγ, pKi: 6.5

PI3Kδ, pIC₅₀: 5.8
PI3Kδ, pKi: 8.0

PI3Kδ-IN-21

PI3Kα, IC₅₀: 7034 nM

PI3Kβ, IC₅₀: 1660 nM

PI3Kδ, IC₅₀: 13.6 nM

PI3K/mTOR Inhibitor-14

PI3K, IC₅₀: 171.4 nM

PI3Kδ-IN-18

PI3Kδ, IC₅₀: 0.1 nM

PI3Kα-IN-14

PI3Kα, IC₅₀: 0.14 nM

PI3Kβ, IC₅₀: 25.89 nM

PI3Kγ, IC₅₀: 2.45 nM

PI3Kδ, IC₅₀: 5.69 nM

CXJ-2

PI3K

COX-2/PI3K-IN-1

PI3K, IC₅₀: 1.14 nM

PI3Kα-IN-20

PI3Kα

PI3Kδ/γ-IN-2

PI3Kγ, IC₅₀: 4.3 nM

PI3Kδ, IC₅₀: 1 nM

PI3Kα-IN-23

PI3Kα-H1047R

PI3K/mTOR Inhibitor-17

PI3Kα, IC₅₀: 0.45 nM

PI3K-IN-10

PI3K

TYM-3-98

PI3Kδ, IC₅₀: 7.1 nM

PI3Kδ-IN-23

PI3Kδ, IC₅₀: 0.27 nM

PI3Kα-IN-8

PI3Kα, IC₅₀: 0.012 μM

PI3Kβ, IC₅₀: 0.21 μM

PI3Kγ, IC₅₀: 0.18 μM

PI3Kδ, IC₅₀: 0.11 μM

PI3Kα-IN-1

PI3Kα, IC₅₀: <0.5 nM

PI3K/VEGFR2-IN-1

PI3K, IC₅₀: 2.21 μM

LTURM 36

PI3Kβ, IC₅₀: 5.0 μM

PI3Kδ, IC₅₀: 0.64 μM

Topoisomerase I/II inhibitor 3

PI3K

mTOR inhibitor-13

PI3Kα, IC₅₀: 119 nM

PI3Kα-IN-24

PI3Kα, IC₅₀: 0.025 μM

mTOR inhibitor-17

PI3Kα, IC₅₀: 1359 nM

PI3K-IN-54

p110α, IC₅₀: 0.22 nM

p110β, IC₅₀: 1.4 nM

p110δ, IC₅₀: 0.38 nM

MIPS-9922

PI3Kβ, IC₅₀: 63 nM

PI3Kδ, IC₅₀: 2200 nM

(S)-GSK-F1

PI3Kα, pIC₅₀: 5.6

PI3Kβ, pIC₅₀: 5.1

PI3Kδ, pIC₅₀: 5.6

PI3Kγ inhibitor 1

PI3Kα, IC₅₀: 10 μM

PI3Kβ, IC₅₀: 10 μM

PI3Kγ, IC₅₀: 100 nM

PI3Kδ, IC₅₀: 100 nM

AS2541019

p110δ

mTOR inhibitor-16

PI3Kα, IC₅₀: 82 nM

AM-0687

PI3Kα, IC₅₀: 17600 nM

PI3Kβ, IC₅₀: 2840 nM

PI3Kγ, IC₅₀: 3530 nM

PI3Kδ, IC₅₀: 2.9 nM

TGX-115

PI3Kβ, IC₅₀: 0.13 μM

PI3Kδ, IC₅₀: 0.63 μM

CAL-130 Racemate

PI3Kδ

PIK-C98

PI3Kα, IC₅₀: 0.59 μM

PI3Kβ, IC₅₀: 1.64 μM

PI3Kγ, IC₅₀: 0.74 μM

PI3Kδ, IC₅₀: 3.65 μM

mTOR inhibitor-10

PI3Kα, IC₅₀: 825 nM

CAL-130

p110α, IC₅₀: 115 nM

p110β, IC₅₀: 56 nM

p110γ, IC₅₀: 6.1 nM

p110δ, IC₅₀: 1.3 nM

PI3kδ inhibitor 1

PI3Kδ, IC₅₀: 3.8 nM

Name
Email *

	Sorry, but the email address you supplied was invalid.

PI3K

PI3K

PI3K Isoform Specific Products:

PI3K Isoform Specific Products:

PI3K Related Products (626)

Antibodies (16)

PI3K Signaling Pathway

PI3K Isoform Comparison

PI3K Related Products (626):